Navigation Links
Cardioxyl Pharmaceuticals Appoints Shi Yin Foo, M.D., Ph.D., As Chief Medical Officer
Date:9/11/2013

CHAPEL HILL, N.C., Sept. 11, 2013 /PRNewswire/ -- Cardioxyl Pharmaceuticals, Inc. announced today the appointment of Shi Yin Foo, M.D., Ph.D., as Chief Medical Officer (CMO). Dr. Foo, who has broad experience in the development of cardiovascular drugs and translational medicine, is well positioned to help Cardioxyl realize the potential of its nitroxyl (HNO) technology for the treatment of patients with serious cardiovascular disease.

Dr. Foo joins Cardioxyl from Novartis, where she was responsible for the establishment and execution of multiple novel programs in heart failure and the cardiorenal space, and is a named inventor on several associated patents applications. She has served as clinical and translational medicine reviewer for numerous studies spanning the full spectrum of Phase I to Phase III clinical trials. Through her experience in both industry and practice, Dr. Foo has developed deep expertise in both acute and chronic heart failure.

"We are very pleased to welcome Dr. Foo to Cardioxyl as our CMO," said Chris Kroeger, M.D., Cardioxyl's President and Chief Executive Officer. "Her unique combination of both early- and late-stage cardiovascular development experience –combined with her extensive clinical experience in the treatment of patients with heart failure – will serve as an excellent complement to Cardioxyl's proprietary expertise in the biology, physiology and chemistry of nitroxyl donors."

Dr. Foo previously was an Assistant Physician in Medicine, Division of Cardiology at Massachusetts General Hospital in Boston, where she served as an attending physician in heart failure/transplantation. Her research focused on the effects of diet on endothelial stem cells and on novel biomarkers to identify these stem cells in vivo. She received the GSK Cardiovascular Foundation Young Investigator Award for this work.

Dr. Foo obtained her M.D. and Ph.D. in Immunology at Stanford University and her MMSc in the Clinical Investigator Training Program at Harvard Medical School. She also holds a B.A. in Molecular, Cellular and Developmental Biology from Princeton University. Dr. Foo was a clinical fellow in Cardiology with subspecialty training in Heart Failure/Transplantation at Massachusetts General Hospital, where she was a winner of the Roman DeSanctis Clinical Scholar Award for clinical expertise. She is board-certified in Internal Medicine and in Cardiovascular Medicine.

"Cardioxyl's nitroxyl donor candidates are supported by remarkable biology, and demonstrate the potential for profound clinical benefit in an under-served patient population," said Dr. Foo. "The Cardioxyl pipeline provides a truly unique opportunity to improve the health and quality of life for patients with heart disease."

About Cardioxyl Pharmaceuticals
Cardioxyl Pharmaceuticals is focused on the discovery and development of new classes of safe and effective therapeutic agents for the treatment of cardiovascular disease. Cardioxyl has developed industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl (HNO) technology. The company's core HNO platform has generated several pre-clinical and clinical candidates. Cardioxyl is a privately held company financed by life science venture investors, including New Enterprise Associates, OrbiMed, Aurora Funds and Osage University Partners.


'/>"/>
SOURCE Cardioxyl Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardioxyl Pharmaceuticals Raises $28 Million In Series B Financing Led By OrbiMed Advisors
2. Caldera Pharmaceuticals Announces Closing of Financing
3. HedgePath Pharmaceuticals Enters into Key Collaboration with Mayne Pharma
4. Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
5. Roche and Inovio Pharmaceuticals partner on Inovios prostate cancer and hepatitis B immunotherapy products
6. UHC to Launch New Specialty Pharmacy Program for Better Continuity of Patient Care, Improved Access to Specialty Pharmaceuticals
7. DelMar Pharmaceuticals and Guangxi Wuzhou Pharmaceuticals Establish Clinical Advisory Board in China
8. Biogen Idec and Isis Pharmaceuticals Announce Strategic Collaboration to Advance Treatment of Neurological Disorders
9. Altaire Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of 9 lots of Carboxymethylcellulose Sodium 0.5% Ophthalmic Solution sold under several brands
10. SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of Astex Pharmaceuticals, Inc.
11. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, Inc., ... development and manufacturing of collagen and mineral based ... today that Bill Messer has joined ... to further leverage the growing portfolio of oral ... Bill joins the Collagen Matrix executive ...
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... ... 24, 2016 , ... People across the U.S. are sharpening their pencils and ... essay contest in which patients and their families pay tribute to a genetic counselor ... National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):